For a 17‑year‑old with an asthma exacerbation, what inhaled corticosteroid–long‑acting β2‑agonist (ICS‑LABA) formulations are available?

Available ICS-LABA Formulations for Adolescents with Asthma

For a 17-year-old with asthma, several ICS-LABA combination inhalers are available, with the most commonly used formulations being budesonide/formoterol (Symbicort), fluticasone propionate/salmeterol (Advair), fluticasone propionate/formoterol, and beclometasone/formoterol.

Primary ICS-LABA Combinations

The following fixed-dose combination products are commercially available and FDA-approved for adolescents:

Budesonide/Formoterol (Symbicort)

• Available as a pressurized metered-dose inhaler (pMDI)
• Typical dosing: 80/4.5 mcg or 160/4.5 mcg per inhalation, 2 inhalations twice daily
• Unique advantage: Can be used as both maintenance and reliever therapy (MART regimen) in patients ≥12 years with moderate-to-severe asthma 1
• Provides rapid bronchodilation due to formoterol's fast onset of action 2

Fluticasone Propionate/Salmeterol (Advair)

• Available as both dry powder inhaler (DPI) and pMDI formulations
• Common strengths: 100/50 mcg, 250/50 mcg, or 500/50 mcg
• Administered twice daily
• Extensively studied with robust efficacy data 3

Fluticasone Propionate/Formoterol

• Combines the potency of fluticasone with the rapid onset of formoterol
• Evidence suggests faster onset of bronchodilation compared to fluticasone/salmeterol 4
• Lower pneumonia risk compared to other ICS-LABA combinations 4

Beclometasone Dipropionate/Formoterol

• Available in Europe and some other markets
• Extra-fine particle formulation allows better lung deposition 5

Clinical Context for a 17-Year-Old

For adolescents aged 12 years and older with moderate-to-severe persistent asthma, the 2020 NAEPP guidelines make a strong recommendation for ICS-formoterol as a single inhaler for both daily controller and reliever therapy over higher-dose ICS alone with SABA or same-dose ICS-LABA with SABA 1.

Key Prescribing Considerations:

Formoterol-containing combinations (budesonide/formoterol or fluticasone/formoterol) offer:

• Rapid symptom relief within 1-3 minutes, comparable to SABA 4, 3
• Ability to use MART strategy, which reduces exacerbation risk 1

Salmeterol-containing combinations (fluticasone/salmeterol):

• Slower onset of action (10-20 minutes)
• Cannot be used as rescue medication
• Requires separate SABA inhaler for quick relief 3

Practical Algorithm for Selection

1. For moderate-to-severe asthma with frequent symptoms: Choose budesonide/formoterol or fluticasone/formoterol to enable MART regimen 1

2. For patients requiring simplicity (one inhaler for everything): Budesonide/formoterol or fluticasone/formoterol with MART approach 6, 7

3. For patients with history of pneumonia or respiratory infections: Consider fluticasone/formoterol (lowest pneumonia risk) 4

4. For cost-sensitive situations: Fluticasone/salmeterol often has better insurance coverage and generic availability

Common Pitfalls to Avoid

• Never prescribe LABA without ICS - this increases mortality risk and exacerbations 8
• Do not use salmeterol-containing products for quick relief - salmeterol has slow onset and is not appropriate for acute symptoms 3
• Avoid SABA-only treatment in adolescents - all patients ≥12 years should receive ICS-containing therapy 6, 7
• Do not assume all ICS-LABA combinations are interchangeable - formoterol-based products enable MART, salmeterol-based do not 1